Scinai Stock Surges on $2.61 Million Private Placement as SCNI Bets on CDMO Expansion
Scinai Immunotherapeutics shares soared 82% Friday after the company announced a $2.61 million private placement and warrant inducement to fund its contract drug-manufacturing and immunotherapy work. The financing includes the sale of 5.2 million ADSs at $0.48 each and new warrants, with closing expected around April 27. Scinai reported $1.6 million cash at year-end and a going-concern warning in its latest filing.